The Bureau of Labor Statistics said its consumer price index rose at only 0.2% in April, bringing the annual increase down to 2.3% from 2.4% despite President Donald Trump’s raft of tariffs that influenced global markets.
THE LATEST NEWS ON MERGERS & ACQUISITIONS, CAPITAL MARKETS AND TECH TRENDS
PHOTO: FREEPIK
US inflation eases, global equities rise as tariff pause lifts sentiment
The Bureau of Labor Statistics said its consumer price index rose at only 0.2% in April, bringing the annual increase down to 2.3% from 2.4% despite President Donald Trump’s raft of tariffs that influenced global markets. Read here
Blackstone targets $5.6B for new GP stakes fund
The world’s largest alternative asset manager is seeking to raise a fresh infusion for its latest vehicle, part of its General Partner Stakes platform, dedicated to acquiring minority stakes in private equity firms. Read here
PHOTO: BLACKSTONE
Hinge targets $3B as IPO markets signal comeback
The California-based digital health startup is eying a valuation of up to $2.98 billion on a fully diluted basis in its initial public offering, signaling thawing of the US IPO market after recent market volatility. Read here
PHOTO: HINGE
NEWS WORTH NOTING
NEWS WORTH NOTING
Anthropic, Google score win by nabbing Harvey
The popular legal artificial intelligence tool will now be using leading foundation models from Anthropic and Google, moving beyond strictly using OpenAI’s as one of its early-backed portfolio companies. Read here
AviLease places order for up to 30 Boeing 737 MAX jets
An aircraft leasing firm owned by Saudi Arabia's sovereign wealth fund has placed an order for up to 30 Boeing 737 MAX jets, the American planemaker has confirmed. Read here
Novo Nordisk in $2.2B fat- loss drug deal with Septerna
The Danish pharmaceutical has struck a collaboration and licensing agreement with the US biotech to develop oral small molecule medicines for obesity and type 2 diabetes. Read here
GSK to acquire liver disease treatment for up to $2B
The British drugmaker is set to acquire efimosfermin, a drug for steatotic liver disease in late-stage trials, from US biotechnology firm Boston Pharmaceuticals. Read here
Aviva's $4.9B Direct Line deal faces antitrust probe
The insurer's bid to become Britain's largest home and motor coverage provider suffered a potential snag after threats of a competition watchdog review. Read here
